You’re putting in the effort. If progress feels frustrating, we’ll take time to understand what you’ve tried, explore what may be getting in the way, and build a practical plan with you.
Your weight is shaped by more than willpower. We listen to what you’ve tried, review your health history and medications, and explore how appetite, sleep, stress, and daily routines may be affecting your progress.
Tell us what success looks like for you: moving more comfortably, improving health markers, keeping up with your family, or feeling more confident in your day. Together, we’ll set realistic goals and decide what support fits.
Concierge members receive discounts on eligible weight-management medicines. We’ll review available options and your individual pricing before you begin.
Medication choices, eligibility, and results vary. We review treatment and monitoring costs with you before starting.
Retatrutide is an investigational triple agonist targeting GIP, GLP-1, and glucagon receptors. It is not FDA approved. Phase 3 results show substantial potential for weight management.
In an 80-week randomized trial of 2,339 adults with obesity without diabetes, average weight reductions were 17.6%, 23.7%, and 25.0% across the three retatrutide groups, compared with 3.9% with placebo. These results include participants regardless of whether they stayed on treatment.
These are group averages, not a prediction of any individual’s result. The study also reported improvements in knee-osteoarthritis pain and sleep-apnea severity in the relevant participant subgroups.
Gastrointestinal side effects were common. Lilly reported nausea in 28.6–42.4% of participants taking retatrutide versus 14.8% with placebo; diarrhea in 25.2–34.1% versus 13.5%; and vomiting in 10.6–25.3% versus 4.8%. Treatment discontinuation due to adverse events ranged from 4.1–11.3%, compared with 4.9% with placebo. Tolerability varied by dose.
Ongoing research is examining longer-term cardiovascular and kidney outcomes and other obesity-related conditions. Trial findings should be considered alongside each person’s health history and the full safety data.
Read the published Phase 3 trial ↗Review Lilly’s detailed safety results ↗Explore the TRIUMPH-Outcomes study ↗Research reviewed October 20, 2026. Research information does not establish availability through SEVA.
Your provider can discuss established treatment options available for your care.
Semaglutide and tirzepatide can cause nausea, vomiting, diarrhea, constipation, and abdominal discomfort. Important risks include pancreatitis, gallbladder problems, and dehydration-related kidney injury. Their labels carry boxed warnings about thyroid C-cell tumors observed in rodents; human risk is unknown. They are contraindicated with a personal or family history of medullary thyroid carcinoma or MEN2.
Pregnancy plans, other medicines, and relevant medical conditions require review. This is a brief overview, not the full prescribing information. Results vary, and a prescription is not guaranteed.
We’ll check in on your progress, how you’re feeling, nutrition, and any medication side effects. Your plan can evolve as your needs change. Keep us informed about new symptoms, other medicines, or pregnancy plans, and review any treatment changes with your prescriber.
Not automatically. Ask about the medication, visits, monitoring tests, and any discounts before treatment. Covered services may be billed to insurance, and medication coverage depends on your plan.
FDA-approved products have defined indications and prescribing information. Nonstandard blends and investigational compounds do not have the same evidence or approval status. Our separate peptide-education page explains those distinctions.
Tell us what matters to you. We’ll listen, explore your goals, and help you take an active role in your health. Start with a complimentary membership conversation, with time for your questions.
Request a Consultation9397 Crown Crest Blvd, Suite 431
Parker, CO 80138
Monday–Friday · 8:00 a.m.–4:45 p.m.
(720) 262-7382